Alembic Pharmaceuticals Ltd - 533573 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
The exchange is hereby informed that the Company will hold Post Results Conference Call on 4th May, 2021 as per the enclosed details. We request you to kindly take the same on record. Alembic Pharmaceuticals Ltd - 533573 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
With reference to the captioned subject, this is to inform the exchange that the Company has received US Food & Drug Administration (USFDA) Final Approval for Doxepin Hydrochloride Capsules USP, 10 mg, 25 mg, 50 mg, 75 mg and 100 mg. Please find enclosed herewith our press release. We request you to kindly take the same on record. ALEMBIC PHARMACEUTICALS LTD. - 533573 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Pursuant to Regulation 39(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform the exchange that the share certificate(s) of the Company has been reported as lost/misplaced and the legal heir(s) of registered shareholder(s) have requested the Company for issue of duplicate share certificate. We enclose herewith an e-mail intimation received from Link Intime India Private Limited, Registrar and Share Transfer Agent giving the proof of the date of receipt of aforesaid information by the Company. We request you to kindly take the same on record. Alembic Pharmaceuticals Ltd - 533573 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose herewith a copy of Notice of Board Meeting published in English and vernacular language (Gujarati) newspaper on 21st April, 2021 in Economic Times English Edition, Indian Express English Edition and Financial Express Gujarati Edition. We request you to kindly take the same on record. Alembic Pharmaceuticals Ltd - 533573 - Board Meeting Intimation for 1. To Consider And Approve Audited Financial Results Of The Company For The Quarter And Financial Year Ended 31St March, 2021. 2. To Consider And Recommend Dividend On Equity Shares, If Any, For The Financial Year Ended 31St March, 2021.
ALEMBIC PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 04/05/2021 ,inter alia, to consider and approve With reference to the captioned matter, the exchange is hereby informed that a Meeting of Board of Directors of the Company will be held on Tuesday, 4th May, 2021, inter-alia to transact the following business: 1. To consider and approve Audited Financial Results of the Company for the quarter and financial year ended 31st March, 2021. 2. To consider and recommend dividend on Equity Shares, if any, for the financial year ended 31st March, 2021. Pursuant to the Company's Code of Conduct for Regulating, Monitoring and Reporting of Trading by Designated Persons and their Immediate Relatives, the trading window for dealing in securities of the Company which was closed from 1st April, 2021, will re-open 48 hours after the declaration of the financial results. We request you to kindly take the same on record. Alembic Pharmaceuticals Ltd - 533573 - Format of the Annual Disclosure to be made by an entity identified as a Large Corporate
Format of the Annual Disclosure to be made by an entity identified as a Large Corporate. Sr. No. Particulars Details 1 Name of Compay ALEMBIC PHARMACEUTICALS LTD. 2 CIN L24230GJ2010PLC061123 3 Report filed for FY 2020-2021 Details of the borrowings (all figures in Rs crore) 4 Incremental borrowing done in FY(a) 0 5 Mandatory borrowing to be done through issuance of debt securities(b) = (25% of a) 0 6 Actual borrowings done through debt securities in FY(c) 0 7 Shortfall in the mandatory borrowing through debt securities, if any (d) = (b) - (c) { If the calculated value is zero or negative, write 'nil'} Nil 8 Reasons for shortfall, if any, in mandatory borrowings through debt securities Not Applicable Name of the Company Secretary :-CHARANDEEP SINGH SALUJADesignation :-COMPANY SECRETARY Name of the Chief Financial Officer :- R K BAHETI Designation : -DIRECTOR FINANCE AND CFO Date: 16/04/2021 Alembic Pharmaceuticals Ltd - 533573 - Format of Initial Disclosure to be made by an entity identified as a Large Corporate
Format of Initial Disclosure to be made by an entity identified as a Large Corporate. Sr. No. Particulars Details 1Name of CompayALEMBIC PHARMACEUTICALS LTD. 2CINL24230GJ2010PLC061123 3 Outstanding borrowing of company as on 31st March / 31st December, as applicable (in Rs cr) 500.00 4Highest Credit Rating during the previous FY AA+STABLE 4aName of the Credit Rating Agency issuing the Credit Rating mentioned in (4)CRISIL LTD. 5Name of Stock Exchange# in which the fine shall be paid, in case of shortfall in the required borrowing under the frameworkNSE We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018. YES Name of the Company Secretary: CHARANDEEP SINGH SALUJA Designation: COMPANY SECRETARY EmailId: charandeep.singh@alembic.co.in Name of the Chief Financial Officer: R K BAHETI Designation: DIRECTOR FINANCE AND CFO EmailId: rajkumar_baheti@alembic.co.in Date: 16/04/2021 Note: In terms para of 3.2(ii) of the circular, beginning F.Y 2022, in the event of shortfall in the mandatory borrowing through debt securities, a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore, an entity identified as LC shall provide, in its initial disclosure for a financial year, the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets. Alembic Pharmaceuticals Ltd - 533573 - Certificate Under Regulation 40(9) Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 For The Half Year Ended 31St March, 2021
With reference to the captioned subject, we enclose herewith Certificate under Regulation 40(9) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 for the half year ended 31st March, 2021, issued by M/s. Samdani Shah & Kabra, Practising Company Secretaries, Vadodara. We request you to kindly take the same on record. Alembic Pharmaceuticals Ltd - 533573 - Compliance Certificate For The Period Ended 31St March, 2021
With reference to the captioned subject, we hereby confirm that all activities in relation to both physical and electronic share transfer facility are maintained by the Company's Registrar and Share Transfer Agent viz. Link Intime India Private Limited, which is a SEBI approved Category-I Registrar & Transfer Agent, registered with the Securities and Exchange Board of India (SEBI Registration Number: INR000004058). We request you to kindly take the same on record.
Alembic Pharma share price jumps 3% on tentative USFDA approval
Alembic has a cumulative total of 140 ANDA approvals (123 final approvals and 17 tentative approvals) from USFDA.